Active Ingredient History
Ruxolitinib (trade names Jakafi and Jakavi, by Incyte Pharmaceuticals and Novartis) is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow. It is also being investigated for the treatment of other types of cancer (such as lymphomas and pancreatic cancer), for polycythemia vera, for plaque psoriasis, and for alopecia areata. Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) known to be associated with dysregulated JAK1 and JAK2 signaling. Ruxolitinib is a Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies. In a mouse model of JAK2V617F-positive MPN, ruxolitinib prevented splenomegaly, preferentially decreased JAK2V617F mutant cells in the spleen and decreased circulating inflammatory cytokines (eg, TNF-α, IL-6). Ruxolitinib was initially synthesized at Incyte Corporation that acquired the rights to develop and commercialize the drug in US. Incyte amended its Collaboration and License Agreement with Novartis, granting Novartis exclusive research, development and commercialization rights for ruxolitinib outside the U.S. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Administration, Topical (Phase 2)
Alopecia Areata (Phase 2)
Anemia (Phase 2)
Anemia, Aplastic (Phase 1/Phase 2)
Arthritis, Rheumatoid (Phase 3)
beta-Thalassemia (Phase 4)
Blood Coagulation Disorders (Phase 1/Phase 2)
Blood Platelet Disorders (Phase 1/Phase 2)
Bone Marrow Cells (Phase 2)
Bone Marrow Diseases (Phase 1/Phase 2)
Breast Carcinoma In Situ (Phase 2)
Breast Neoplasms (Phase 2)
Bronchiolitis (Phase 2)
Cachexia (Phase 2)
Carcinoma, Intraductal, Noninfiltrating (Phase 2)
Carcinoma, Lobular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 1/Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Colorectal Neoplasms (Phase 2)
Coronavirus (Phase 1/Phase 2)
Coronavirus Infections (Phase 2)
COVID-19 (Phase 3)
Cytokine Release Syndrome (Phase 4)
Dermatitis, Atopic (Phase 4)
Dermatitis, Seborrheic (Phase 2)
Dermatomyositis (Phase 4)
Digital Dermatitis (Phase 1/Phase 2)
Eczema (Phase 3)
Eosinophilia (Phase 2)
Fallopian Tube Neoplasms (Phase 1/Phase 2)
Glioblastoma (Phase 1)
Glioma (Phase 1)
Graft vs Host Disease (Phase 4)
Hamartoma (Phase 1/Phase 2)
Healthy Volunteers (Phase 1)
Hematologic Diseases (Phase 1/Phase 2)
Hematologic Neoplasms (Phase 2)
Hematopoietic Stem Cell Transplantation (Phase 4)
Hemorrhagic Disorders (Phase 1/Phase 2)
Hepatomegaly (Phase 2)
Hidradenitis Suppurativa (Phase 2)
HIV Infections (Phase 2)
Hodgkin Disease (Phase 2)
Hypereosinophilic Syndrome (Phase 2)
Inflammatory Breast Neoplasms (Phase 2)
Intestinal Neoplasms (Phase 1/Phase 2)
Janus Kinases (Phase 2)
Leukemia (Phase 2)
Leukemia, Eosinophilic, Acute (Phase 2)
Leukemia, Large Granular Lymphocytic (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Lymphoid (Phase 1)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Monocytic, Acute (Phase 2)
Leukemia, Myeloid, Accelerated Phase (Phase 1/Phase 2)
Leukemia, Myeloid, Acute (Phase 4)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Leukemia, Myelomonocytic, Acute (Phase 1/Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Leukemia, Neutrophilic, Chronic (Phase 2)
Leukemia, Prolymphocytic, T-Cell (Phase 1)
Lichen Planus (Phase 2)
Lichen Sclerosus et Atrophicus (Phase 2)
Lung Neoplasms (Phase 2)
Lupus Erythematosus, Discoid (Phase 2)
Lymphohistiocytosis, Hemophagocytic (Phase 4)
Lymphoma (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 4)
Macrophage Activation Syndrome (Phase 3)
Malaria (Phase 1)
Multiple Myeloma (Phase 2)
Mutation (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 3)
Necrobiosis Lipoidica (Phase 2)
Neoplasm Metastasis (Phase 1)
Neoplasm, Residual (Phase 1/Phase 2)
Neoplasms (Phase 2)
Organ Transplantation (Phase 2)
Ovarian Neoplasms (Phase 1/Phase 2)
Pancreatic Neoplasms (Phase 3)
Pneumonia (Phase 1/Phase 2)
Polycythemia Vera (Phase 4)
Polyendocrinopathies, Autoimmune (Phase 2)
Primary Myelofibrosis (Phase 4)
Prostatic Neoplasms (Phase 2)
Protein-Tyrosine Kinases (Phase 1/Phase 2)
Prurigo (Phase 3)
Psoriasis (Phase 2)
Recombinant Fusion Proteins (Phase 2)
Respiratory Distress Syndrome (Phase 2)
SARS-CoV-2 (Phase 2/Phase 3)
Splenomegaly (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Thalassemia (Phase 4)
Thrombocythemia, Essential (Phase 3)
Thrombocytopenia (Phase 2)
Thrombocytosis (Phase 1/Phase 2)
Vitiligo (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue